Overview: Factor XIII Clot Solubility TestIntroduction: The Factor XIII Clot Solubility Test assesses factor XIII activity to diagnose clotting disorders, causing delayed bleeding. Following 2023 ASH guidelines, it uses a clotting assay for high specificity, aiding in coagulation screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in coagulation for patients with suspected factor XIII deficiency.
Other Names: Factor XIII Assay, Clot Stability Test.
FDA Status: Laboratory-developed test (LDT), meeting coagulation standards for diagnostic accuracy.
Historical Milestone: Factor XIII testing began in the 1960s with coagulation research. Clot solubility assays emerged in the 1970s, and by the 2000s, standardized methods improved accuracy.
Purpose: Diagnoses factor XIII deficiency, guides factor replacement therapy, and monitors clot stability in patients with delayed bleeding.
Test Parameters: 1. Factor XIII Clot Solubility
Pretest Condition: No fasting required. Collect plasma at any time. Report symptoms like delayed bleeding, and list medications like factor concentrates.
Specimen: 2-4 mL plasma (NaCit). Centrifuge within 1 hour. Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document delayed bleeding or history of factor XIII deficiency. Include current medications, especially factor concentrates.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for factor replacement therapy.
Procedural Considerations: Uses a clot solubility assay to assess factor XIII activity. Results are available in 3-5 days, supporting clinical decisions.
Factors Affecting Result Accuracy: Factor concentrates or improper storage can affect results. Hemolysis may reduce accuracy.
Clinical Significance: Abnormal clot solubility suggests factor XIII deficiency, prompting factor replacement therapy. Normal results may require further testing.
Specialist Consultation: Consult a hematologist for result interpretation.
Additional Supporting Tests: Factor XIII antigen test, aPTT, or bleeding time to confirm factor XIII deficiency.
Test Limitations: Results may be affected by recent factor therapy. Clinical correlation is required.
References: ASH Hemophilia Guidelines, 2023; Blood, Peyvandi F, 2022.
